Business Wire

PIXIE-DUST-TECHNOLOGIES

20.12.2023 04:01:34 CET | Business Wire | Press release

Share
“Defy Dementia with Sound.” Pixie Dust Technologies, Shionogi and Shionogi Healthcare create Gamma Wave Sound to boost everyday cognitive care.

Pixie Dust Technologies, Inc., Shionogi & Co., Ltd, and Shionogi Healthcare Co., Ltd released “Memory” and “Tomorrow”, two audio experiences incorporating gamma wave technology1 designed to provide dementia patients with an additional tool that they can use to care for their cognitive function.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231219774481/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Gamma Wave Sound (Graphic: Business Wire)

It is estimated that every 3 seconds, someone develops dementia – a general term for a decline in mental ability severe enough to interfere with daily life. By 2050, more than 150 million people globally will live with dementia. Patients can preserve their quality of life and enhance overall wellness by engaging in activities that stimulate the brain.

Ongoing studies2345 demonstrate that repeated exposure to 40Hz gamma waves can promote brain function by reducing white matter atrophy and myelin loss, which contribute to Alzheimer’s disease progression. Data validated by Pixie Dust Technologies Inc. and Shionogi & Co., Ltd confirmed that gamma wave power and its entrainment increased when listening to amplitude-modulated 40Hz sounds, suggesting that such sounds can be clinically applied to dementia prevention as a non-invasive method.

The Dementia Care Project by Gamma Wave Sound is an initiative designed to help people care for their cognitive function through auditory stimulation. Turning gamma waves technology into a readily available audio experience presents new possibilities in providing cognitive stimulation for dementia.

Six major companies across industries in Japan have come together to form the alliance to boost dementia care as part of the Dementia Care Project by Gamma Wave Sound. These diverse companies share a common goal – to bring integrated daily care of cognitive function through its public touchpoints.

The number of participating companies continues to grow under the initiative, with gamma wave sound experience being brought to places where sound can be heard, such as the largest shopping malls and fitness gym’s exercising program, and local onsen resting spots in Japan.

Expanding to other countries as an international effort, Alii Palau Airlines, which provides direct flight service between Singapore and Palau, is playing both gamma wave audio tracks “Memory” and “Tomorrow”.

Furthermore, music artists who support the initiative have released the Gamma Wave Sound edit of their tracks, accelerating the efforts to deliver Gamma Wave Sound through entertainment.

The original soundtracks are available for download on YouTube (Memory (Gamma Wave Sound Edit) , Tomorrow (Gamma Wave Sound Edit)) , Spotify, Apple Music Podcast.

For more information, please visit our website at:  https://www.project.gammawavesound.com/home-1

References

1 Patent filed in Japan; patented technology processes audio by performing 40Hz amplitude modulation on partial signals included in input audio.
2 Martorell, A. J., Paulson, A. L., Suk, H. J., Abdurrob, F., Drummond, G. T., Guan, W., ... & Tsai, L. H. (2019). Multi-sensory gamma stimulation ameliorates Alzheimer’s-associated pathology and improves cognition. Cell, 177(2), 256-271.
3 Cognito Therapeutics Presents New MRI Data Showing Non-Invasive Gamma Stimulation Therapy Reduces Brain Atrophy and Myelin Loss in Alzheimer’s Disease. (2023, June 17).
4 Business Wire: Cognito Therapeutics Announces First Patient Enrollment in US Pivotal Study HOPE
5-1 Business Wire: Cognito Therapeutics Announces Proprietary Gamma Sensory Stimulation for 6-Months Reduces White Matter Atrophy in Alzheimer’s Disease Patients
5-2 2023 Association for Research in Otolaryngology Midwinter Meeting Abstract Book, pp.443-444 (2023).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231219774481/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye